Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15270722 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9490031 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29003720 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL329082 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15270977 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11407928 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11782479 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14402487 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29003717 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15270678 | 0.98 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024031242-A1 | METHOD FOR SYNTHESIZING ARYL BENZYL THIOETHER COMPOUND | 苏州大学 | 2024-02-15 | — | — | WO | claimed |
| CN-115286547-A | Method for synthesizing aryl benzyl sulfide compound | 苏州大学 | 2022-11-04 | — | — | CN | claimed |
| WO-2024031242-A1 | METHOD FOR SYNTHESIZING ARYL BENZYL THIOETHER COMPOUND | 苏州大学 | 2024-02-15 | — | — | WO | disclosed |
| CN-115286547-B | Method for synthesizing aryl benzyl thioether compound | 苏州大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-115286547-B | Method for synthesizing aryl benzyl thioether compound | 苏州大学 | 2023-11-03 | — | — | CN | disclosed |
| EP-4230620-A1 | SUBSTITUTED N-AMINO-N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-08-23 | — | — | EP | disclosed |
| CN-115286547-A | Method for synthesizing aryl benzyl sulfide compound | 苏州大学 | 2022-11-04 | — | — | CN | disclosed |
| CN-115286547-A | Method for synthesizing aryl benzyl sulfide compound | 苏州大学 | 2022-11-04 | — | — | CN | disclosed |
| CN-115286547-A | Method for synthesizing aryl benzyl sulfide compound | 苏州大学 | 2022-11-04 | — | — | CN | disclosed |
| EP-3728237-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-9650456-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| CN-1296349-C | Novel propionic acid derivatives | ASAHI KASEI PHARMA CORP (JP) | 2007-01-24 | — | — | CN | disclosed |
| WO-2006094633-A1 | 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199816-A1 | Aryl sulfonyl piperidines | GILLESPIE PAUL | 2006-09-07 | — | — | US | disclosed |
| US-7056708-B2 | Method of producing polyhydroxyalkanoate from alkane having residue containing aromatic ring in its molecule | CANON KABUSHIKI KAISHA (JP) | 2006-06-06 | — | — | US | disclosed |
| EP-1367078-B1 | Method of producing polyhydroxyalkanoate from alkane having residue containing aromatic ring in its molecule | CANON KK (JP) | 2006-04-19 | — | — | EP | disclosed |
| CN-1649834-A | Novel propionic acid derivatives | ASAHI KASEI PHARMA CORP (JP) | 2005-08-03 | — | — | CN | disclosed |
| EP-1367078-A2 | Method of producing polyhydroxyalkanoate from alkane having residue containing aromatic ring in its molecule | CANON KABUSHIKI KAISHA (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-20030207412-A1 | Method of producing polyhydroxyalkanoate from alkane having residue containing aromatic ring in its molecule | CANON KABUSHIKI KAISHA (JP) | 2003-11-06 | — | — | US | disclosed |
| US-4027037-A | ARTHROPOD METAMORPHOSIS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199816-A1 | Aryl sulfonyl piperidines | GPR119, SLC5A2, GLS2 | CYP2C19 94/4885CYP1A2 83/4885CYP3A4 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.